{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:39:46Z","timestamp":1790300386092,"version":"4.1.0"},"reference-count":94,"publisher":"Georg Thieme Verlag KG","issue":"07","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Venous thromboembolism is a common cause of morbidity and mortality in children with renal disease. To properly treat and prevent thromboembolism in this patient population, it is important to be familiar with the multitude of anticoagulant agents currently available. Many anticoagulant drugs undergo some extent of renal elimination. There are important considerations for the selection, dosing, and monitoring of anticoagulant drugs for patients with renal impairment due to various pharmacokinetic alterations that may occur. While there are data to help guide dosing and monitoring in adults, evidence regarding renal dose adjustment of many anticoagulant drugs in children are limited. For the clinician, anticoagulation management in children with renal impairment presents unique challenges. In addition to considering overall bleeding risk, the extent of renal impairment may vary by patient, making a one-size-fits-all approach to managing these patients difficult. These factors, combined with limited data, can make managing anticoagulation in children with renal impairment a challenge. Therefore, the focus of this review will be to describe the pharmacokinetics of the following anticoagulants in children with impaired renal function: unfractionated heparin, enoxaparin, dalteparin, rivaroxaban, apixaban, edoxaban, fondaparinux, bivalirudin, argatroban, dabigatran, and warfarin.<\/jats:p>","DOI":"10.1055\/a-2546-0126","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T19:49:55Z","timestamp":1743191395000},"page":"776-787","source":"Crossref","is-referenced-by-count":2,"title":["Anticoagulants in Children with Renal Impairment: A Narrative Review"],"prefix":"10.1055","volume":"51","author":[{"given":"Amy L.","family":"Kiskaddon","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland"},{"name":"Division of Hematology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland"},{"name":"Institute for Clinical and Translational Research, Johns Hopkins All Children's, St. Petersburg, Florida"},{"name":"Department of Pharmacy, Johns Hopkins All Children's Hospital, St. Petersburg, Florida"},{"name":"Heart Institute, Johns Hopkins All Children's Hospital, St. Petersburg, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Witt","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"Betensky","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland"},{"name":"Cancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St. Petersburg, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony A.","family":"Sochet","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland"},{"name":"Division of Pediatric Critical Care Medicine, Department of Medicine, Johns Hopkins All Children's Hospital, St. Petersburg, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Memken","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Johns Hopkins All Children's Hospital, St. Petersburg, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Male","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil A.","family":"Goldenberg","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland"},{"name":"Institute for Clinical and Translational Research, Johns Hopkins All Children's, St. Petersburg, Florida"},{"name":"Cancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St. Petersburg, Florida"},{"name":"Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"issue":"05","key":"ref1","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/MCP.0b013e32832ee371","article-title":"Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms","volume":"15","author":"K Wattanakit","year":"2009","journal-title":"Curr Opin Pulm Med"},{"issue":"08","key":"ref2","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/PCC.0000000000002754","article-title":"Thromboembolic complications of vascular catheters used for pediatric continuous renal replacement therapy: Prevalence in a single-center, retrospective cohort","volume":"22","author":"I Szeps","year":"2021","journal-title":"Pediatr Crit Care Med"},{"key":"ref3","first-page":"219","volume-title":"Thrombosis and embolie. In: Gesammelte Abhandlungen zur Wissenshaftlichen Medicin","author":"R Virchow","year":"1856"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.thromres.2018.10.031","article-title":"Central venous catheter-related venous thrombosis in children with end-stage renal disease undergoing hemodialysis","volume":"172","author":"N Mandel-Shorer","year":"2018","journal-title":"Thromb Res"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/asheducation-2016.1.188","article-title":"Thrombosis and anticoagulation in the setting of renal or liver disease","volume":"2016","author":"C Ribic","year":"2016","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"03","key":"ref6","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1378\/chest.125.3.856","article-title":"Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin","volume":"125","author":"N Thorevska","year":"2004","journal-title":"Chest"},{"key":"ref7","first-page":"1","article-title":"KDIGO Clinical Practice Guideline for Acute Kidney Injury","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO)Acute Kidney Injury Work Group","year":"2012","journal-title":"Kidney int Suppl"},{"issue":"05","key":"ref8","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1373\/clinchem.2011.177741","article-title":"Closing the gaps in pediatric laboratory reference intervals: a CALIPER database of 40 biochemical markers in a healthy and multiethnic population of children","volume":"58","author":"D A Colantonio","year":"2012","journal-title":"Clin Chem"},{"issue":"05","key":"ref9","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0022-3476(78)80133-4","article-title":"Developmental patterns of renal functional maturation compared in the human neonate","volume":"92","author":"B S Arant Jr","year":"1978","journal-title":"J Pediatr"},{"key":"ref10","first-page":"21","volume-title":"Renal function during fetal life","author":"J E Robillard","year":"1999"},{"issue":"06","key":"ref11","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/j.1875-9114.1996.tb03022.x","article-title":"Renal drug transport: a review","volume":"16","author":"R Bendayan","year":"1996","journal-title":"Pharmacotherapy"},{"issue":"07","key":"ref12","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2215\/CJN.00340118","article-title":"Clinical pharmacokinetics in kidney disease: Fundamental principles","volume":"13","author":"T N Lea-Henry","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"05","key":"ref13","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/pbc.21653","article-title":"Current practice perspectives on the management of thrombosis in children with renal insufficiency: the results of a survey of pediatric hematologists in North America","volume":"51","author":"A A Sharathkumar","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/pharmacy8010018","article-title":"Drug dosing considerations in critically ill patients receiving continuous renal replacement therapy","volume":"8","author":"S M Jang","year":"2020","journal-title":"Pharmacy (Basel)"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/phar.2858","article-title":"Practical considerations for individualizing drug dosing in critically ill adults receiving renal replacement therapy","volume":"43","author":"S Kanji","year":"2023","journal-title":"Pharmacotherapy"},{"issue":"11","key":"ref16","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/ki.2011.322","article-title":"Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"80","author":"G R Matzke","year":"2011","journal-title":"Kidney Int"},{"issue":"02","key":"ref17","doi-asserted-by":"crossref","first-page":"e737S","DOI":"10.1378\/chest.11-2308","article-title":"Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"P Monagle","year":"2012","journal-title":"Chest"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1542\/peds.63.4.552","article-title":"Effect of heparinization of fluids infused through an umbilical artery catheter on catheter patency and frequency of complications","volume":"63","author":"K Rajani","year":"1979","journal-title":"Pediatrics"},{"issue":"03","key":"ref19","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1542\/peds.2008-2052","article-title":"Unfractionated heparin therapy in infants and children","volume":"123","author":"F Newall","year":"2009","journal-title":"Pediatrics"},{"issue":"18","key":"ref20","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1182\/blood-2015-06-651661","article-title":"Monitoring unfractionated heparin in children: a parallel-cohort randomized controlled trial comparing 2 dose protocols","volume":"126","author":"A Hanslik","year":"2015","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.thromres.2017.07.006","article-title":"Should we abandon the APTT for monitoring unfractionated heparin?","volume":"157","author":"D RJ Arachchillage","year":"2017","journal-title":"Thromb Res"},{"issue":"07","key":"ref22","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/jth.14846","article-title":"Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis","volume":"18","author":"A Tripodi","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref23","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/ckj\/sfu080","article-title":"Anticoagulation in chronic kidney disease patients-the practical aspects","volume":"7","author":"S Hughes","year":"2014","journal-title":"Clin Kidney J"},{"issue":"04","key":"ref24","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1527-3466.2005.tb00177.x","article-title":"Bivalirudin: pharmacology and clinical applications","volume":"23","author":"N W Shammas","year":"2005","journal-title":"Cardiovasc Drug Rev"},{"issue":"09","key":"ref25","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1111\/jth.13057","article-title":"UNBLOCK: an open-label, dose-finding, pharmacokinetic and safety study of bivalirudin in children with deep vein thrombosis","volume":"13","author":"S H O'Brien","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/ajcp\/aqac131","article-title":"Monitoring direct thrombin inhibitors with calibrated diluted thrombin time vs activated partial thromboplastin time in pediatric patients","volume":"159","author":"R A Hasan","year":"2023","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"ref27","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1345\/aph.1Q177","article-title":"Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia","volume":"45","author":"L V Tsu","year":"2011","journal-title":"Ann Pharmacother"},{"issue":"11","key":"ref28","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1097\/MAT.0000000000001818","article-title":"Evaluation of bivalirudin dosing in pediatric extracorporeal membrane oxygenation with renal insufficiency or renal replacement therapy","volume":"68","author":"M Hamzah","year":"2022","journal-title":"ASAIO J"},{"issue":"11","key":"ref29","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/MAT.0000000000001681","article-title":"Impact of continuous renal replacement therapy on bivalirudin dosing in pediatric extracorporeal membrane oxygenation","volume":"68","author":"M A Lahart","year":"2022","journal-title":"ASAIO J"},{"issue":"07","key":"ref30","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1055\/s-0043-1772838","article-title":"Anticoagulation with intravenous direct thrombin inhibitors in pediatric extracorporeal membrane oxygenation: A systematic review of the literature","volume":"49","author":"A L Kiskaddon","year":"2023","journal-title":"Semin Thromb Hemost"},{"issue":"04","key":"ref31","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2125.2011.03916.x","article-title":"Direct thrombin inhibitors","volume":"72","author":"C J Lee","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"07","key":"ref32","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/pbc.22852","article-title":"Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokinetic study","volume":"56","author":"G Young","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"02","key":"ref33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11239-019-01961-3","article-title":"Evaluation of intravenous direct thrombin inhibitor monitoring tests: Correlation with plasma concentrations and clinical outcomes in hospitalized patients","volume":"49","author":"J T Beyer","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"07","key":"ref34","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/hq0701.093686","article-title":"Mechanism of action and pharmacology of unfractionated heparin","volume":"21","author":"J Hirsh","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0049-3848(03)00059-8","article-title":"An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial","volume":"109","author":"P Massicotte","year":"2003","journal-title":"Thromb Res"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0049-3848(03)00099-9","article-title":"An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial","volume":"109","author":"P Massicotte","year":"2003","journal-title":"Thromb Res"},{"issue":"01","key":"ref37","doi-asserted-by":"crossref","first-page":"e2022056726","DOI":"10.1542\/peds.2022-056726","article-title":"Enoxaparin Thromboprophylaxis in Children Hospitalized for COVID-19: A Phase 2 Trial","volume":"150","author":"A A Sochet","year":"2022","journal-title":"Pediatrics"},{"issue":"04","key":"ref38","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1097\/CCM.0000000000004848","article-title":"Age-dependent heterogeneity in the efficacy of prophylaxis with enoxaparin against catheter-associated thrombosis in critically ill children: A post hoc analysis of a Bayesian phase 2b randomized clinical trial","volume":"49","author":"E VS Faustino","year":"2021","journal-title":"Crit Care Med"},{"issue":"11","key":"ref39","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1111\/jth.12716","article-title":"Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism","volume":"12","author":"S H O'Brien","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref40","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1177\/1060028017734234","article-title":"Population pharmacokinetics of enoxaparin in pediatric patients","volume":"52","author":"B S Moffett","year":"2018","journal-title":"Ann Pharmacother"},{"issue":"06","key":"ref41","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.thromres.2014.03.036","article-title":"Subcutaneous enoxaparin for therapeutic anticoagulation in hemodialysis patients","volume":"133","author":"T K Pon","year":"2014","journal-title":"Thromb Res"},{"issue":"07","key":"ref42","doi-asserted-by":"crossref","first-page":"e1040","DOI":"10.1097\/MPH.0000000000002045","article-title":"Management of anticoagulation therapy in patients with thromboembolism in the context of renal dysfunction: challenging cases and practical algorithms","volume":"43","author":"A Bahabri","year":"2021","journal-title":"J Pediatr Hematol Oncol"},{"issue":"01","key":"ref43","first-page":"104","article-title":"A distinctive approach to venous thromboembolism treatment in a pediatric, hemodialysis patient: a case report","volume":"26","author":"J Koury","year":"2021","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"08","key":"ref44","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.3390\/ph16081166","article-title":"The impact of continuous veno-venous hemodiafiltration on the efficacy of administration of prophylactic doses of enoxaparin: a prospective observational study","volume":"16","author":"A Aszkie\u0142owicz","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"01","key":"ref45","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11239-015-1315-2","article-title":"Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism","volume":"41","author":"M A Smythe","year":"2016","journal-title":"J Thromb Thrombolysis"},{"issue":"02","key":"ref46","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.thromres.2015.05.017","article-title":"A retrospective analysis of outcomes of dalteparin use in pediatric patients: a single institution experience","volume":"136","author":"D Warad","year":"2015","journal-title":"Thromb Res"},{"issue":"12","key":"ref47","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1007\/s00467-018-4032-1","article-title":"Dalteparin anticoagulation in paediatric home haemodialysis","volume":"33","author":"M Lutkin","year":"2018","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"ref48","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1111\/jth.13856","article-title":"Evaluation of the age-dependent dosing recommendations for the administration of daily tinzaparin in children with thrombosis","volume":"15","author":"K M Musgrave","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref49","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/PCC.0000000000000640","article-title":"Higher tinzaparin dosing is needed to achieve target anti-xa levels in pediatric cardiac intensive care patients","volume":"17","author":"P P Roeleveld","year":"2016","journal-title":"Pediatr Crit Care Med"},{"issue":"06","key":"ref50","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1160\/TH05-03-0215","article-title":"Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events","volume":"94","author":"S Kuhle","year":"2005","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref51","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s40256-019-00382-0","article-title":"Tinzaparin sodium pharmacokinetics in patients with chronic kidney disease: practical implications","volume":"20","author":"H Helfer","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"issue":"04","key":"ref52","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1160\/TH06-09-0513","article-title":"Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study","volume":"97","author":"I Mah\u00e9","year":"2007","journal-title":"Thromb Haemost"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.thromres.2018.11.031","article-title":"Study of the bioaccumulation of tinzaparin in renally impaired patients when given at prophylactic doses - The STRIP study","volume":"174","author":"D Projean","year":"2019","journal-title":"Thromb Res"},{"issue":"01","key":"ref54","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/imj.15010","article-title":"Tinzaparin for venous thromboembolism in patients with renal impairment: a single-centre, prospective pilot study","volume":"53","author":"J Yeung","year":"2023","journal-title":"Intern Med J"},{"issue":"06","key":"ref55","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1586\/erc.09.19","article-title":"Fondaparinux: an overview","volume":"7","author":"S K Nadar","year":"2009","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"03","key":"ref56","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.thromres.2014.07.026","article-title":"FondaKIDS II: long-term follow-up data of children receiving fondaparinux for treatment of venous thromboembolic events","volume":"134","author":"R H Ko","year":"2014","journal-title":"Thromb Res"},{"issue":"04","key":"ref57","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/8755122514567316","article-title":"Safety and efficacy of fondaparinux in renal impairment","volume":"31","author":"M H Al-Shaer","year":"2015","journal-title":"J Pharm Technol"},{"issue":"06","key":"ref58","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1160\/TH11-09-0640","article-title":"Venous thromboembolism prevention with fondaparinux 1.5\u2009mg in renally impaired patients undergoing major orthopaedic surgery. A real-world, prospective, multicentre, cohort study","volume":"107","author":"P Mismetti","year":"2012","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref59","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/MBC.0b013e328323da86","article-title":"Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5\u2009mg once daily in the prevention of venous thromboembolism in renally impaired patients","volume":"20","author":"A G Turpie","year":"2009","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"10","key":"ref60","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1111\/bcp.13663","article-title":"Incidence and risk factors of major bleeding following major orthopaedic surgery with fondaparinux thromboprophylaxis. A time-to-event analysis","volume":"84","author":"P J Zufferey","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"06","key":"ref61","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1160\/TH07-07-0444","article-title":"Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis","volume":"98","author":"R M Kalicki","year":"2007","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref62","doi-asserted-by":"crossref","first-page":"198","DOI":"10.5414\/CPP46198","article-title":"Use of fondaparinux as an anticoagulant during hemodialysis: a preliminary study","volume":"46","author":"K I Sombolos","year":"2008","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"12","key":"ref63","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1093\/ndt\/gft293","article-title":"Fondaparinux as an alternative to vitamin K antagonists in haemodialysis patients","volume":"28","author":"M M Speeckaert","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"03","key":"ref64","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/1060028014563325","article-title":"Clinical experience with prophylactic fondaparinux in critically ill patients with moderate to severe renal impairment or renal failure requiring renal replacement therapy","volume":"49","author":"J Cope","year":"2015","journal-title":"Ann Pharmacother"},{"issue":"01","key":"ref65","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00228-021-03220-y","article-title":"Population pharmacokinetics-pharmacodynamics of fondaparinux in dialysis-dependent chronic kidney disease patients undergoing chronic renal replacement therapy","volume":"78","author":"D Michali\u010dkov\u00e1","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"issue":"04","key":"ref66","first-page":"303","article-title":"Fondaparinux in an obese child with heparin-induced thrombocytopenia and a history of renal failure","volume":"18","author":"P N Johnson","year":"2013","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"08","key":"ref67","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/MPH.0b013e3181256ba5","article-title":"Treatment of thrombosis with fondaparinux (Arixtra) in a patient with end-stage renal disease receiving hemodialysis therapy","volume":"29","author":"A A Sharathkumar","year":"2007","journal-title":"J Pediatr Hematol Oncol"},{"issue":"04","key":"ref68","first-page":"318","article-title":"Fondaparinux monitoring: Need for a local fondaparinux-calibrated anti-factor Xa assay","volume":"18","author":"P N Johnson","year":"2013","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"20","key":"ref69","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1161\/01.CIR.0000038501.87442.02","article-title":"Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers","volume":"106","author":"N R Bijsterveld","year":"2002","journal-title":"Circulation"},{"issue":"01","key":"ref70","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s13054-024-05014-x","article-title":"Andexanet alpha versus four-factor prothrombin complex concentrate in DOACs anticoagulation reversal: an updated systematic review and meta-analysis","volume":"28","author":"D Orso","year":"2024","journal-title":"Crit Care"},{"issue":"06","key":"ref72","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.thromres.2010.09.008","article-title":"The mechanism of action of rivaroxaban\u2013an oral, direct Factor Xa inhibitor\u2013compared with other anticoagulants","volume":"127","author":"M M Samama","year":"2011","journal-title":"Thromb Res"},{"issue":"01","key":"ref73","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S2352-3026(19)30219-4","article-title":"Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial","volume":"7","author":"C Male","year":"2020","journal-title":"Lancet Haematol"},{"issue":"22","key":"ref74","doi-asserted-by":"crossref","first-page":"e021765","DOI":"10.1161\/JAHA.120.021765","article-title":"Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study","volume":"10","author":"B W McCrindle","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"03","key":"ref75","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40256-023-00579-4","article-title":"Updated Renal Dosage Recommendations for rivaroxaban in patients experiencing or at risk of thromboembolic disease","volume":"23","author":"A A Volkl","year":"2023","journal-title":"Am J Cardiovasc Drugs"},{"issue":"02","key":"ref76","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000535546","article-title":"Anticoagulation in patients with chronic kidney disease","volume":"55","author":"E J Elenjickal","year":"2024","journal-title":"Am J Nephrol"},{"issue":"08","key":"ref77","doi-asserted-by":"crossref","first-page":"e034176","DOI":"10.1161\/JAHA.123.034176","article-title":"Anticoagulation for patients with concomitant atrial fibrillation and end-stage renal disease: A systematic review and network meta-analysis","volume":"13","author":"T W Kao","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"01","key":"ref78","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.thromres.2015.05.001","article-title":"Direct oral anticoagulants (DOACs) in the laboratory: 2015 Review","volume":"136","author":"D M Adcock","year":"2015","journal-title":"Thromb Res"},{"issue":"03","key":"ref79","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12325-012-0003-2","article-title":"Apixaban: an oral direct factor-xa inhibitor","volume":"29","author":"D Jim\u00e9nez","year":"2012","journal-title":"Adv Ther"},{"issue":"01","key":"ref81","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/S2352-3026(23)00314-9","article-title":"Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial","volume":"11","author":"S H O'Brien","year":"2024","journal-title":"Lancet Haematol"},{"issue":"24","key":"ref82","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.jacc.2023.10.010","article-title":"Apixaban for prevention of thromboembolism in pediatric heart disease","volume":"82","author":"R M Payne","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"03","key":"ref83","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2146\/ajhp150821","article-title":"Edoxaban: A direct oral anticoagulant","volume":"74","author":"M Poulakos","year":"2017","journal-title":"Am J Health Syst Pharm"},{"issue":"05","key":"ref84","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/rth2.12352","article-title":"The Edoxaban Hokusai VTE PEDIATRICS Study: An open-label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease","volume":"4","author":"C H van Ommen","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"24","key":"ref85","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.jacc.2022.09.031","article-title":"Edoxaban for thromboembolism prevention in pediatric patients with cardiac disease","volume":"80","author":"M A Portman","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"ref86","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1124\/dmd.112.046888","article-title":"Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans","volume":"40","author":"M S Bathala","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"01","key":"ref87","first-page":"155","article-title":"In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate","volume":"98","author":"W Wienen","year":"2007","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref88","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/S2352-3026(20)30368-9","article-title":"Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b\/3, non-inferiority trial","volume":"8","author":"J Halton","year":"2021","journal-title":"Lancet Haematol"},{"issue":"04","key":"ref89","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1160\/TH14-06-0547","article-title":"Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis","volume":"113","author":"D A Parasrampuria","year":"2015","journal-title":"Thromb Haemost"},{"issue":"08","key":"ref90","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1111\/j.1538-7836.2005.01419.x","article-title":"The vitamin K cycle","volume":"3","author":"D W Stafford","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"09","key":"ref91","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood.V94.9.3007","article-title":"Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients","volume":"94","author":"W Streif","year":"1999","journal-title":"Blood"},{"issue":"08","key":"ref92","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1046\/j.1538-7836.2003.00256.x","article-title":"Acenocoumarol therapy in pediatric patients","volume":"1","author":"M Bonduel","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref93","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1055\/s-0038-1642427","article-title":"Oral anticoagulation therapy in pediatric patients: a prospective study","volume":"71","author":"M Andrew","year":"1994","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref94","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.thromres.2004.12.017","article-title":"Oral anticoagulation therapy in children","volume":"118","author":"M M Bonduel","year":"2006","journal-title":"Thromb Res"},{"issue":"09","key":"ref95","first-page":"1633","article-title":"American Heart Association\/American College of Cardiology Foundation guide to warfarin therapy","volume":"41","author":"J Hirsh","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"05","key":"ref96","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1053\/j.ajkd.2010.05.023","article-title":"Warfarin dosing in patients with impaired kidney function","volume":"56","author":"N A Limdi","year":"2010","journal-title":"Am J Kidney Dis"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2546-0126.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:33:34Z","timestamp":1757720014000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2546-0126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":94,"journal-issue":{"issue":"07","published-online":{"date-parts":[[2025,9,12]]},"published-print":{"date-parts":[[2025,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2546-0126","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]}}}